This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns. But what if there's more to the picture than just cholesterol?
Only when you have a clear idea of those three factors can you decide whether or not to take a medication to lower your LDL cholesterol. I use statins in the question posed above because that is what most people think and, in fact, what they will start with when looking to lower their LDL cholesterol with a medication. Not zero risk.
Nature Reviews Cardiology, Published online: 18 November 2024; doi:10.1038/s41569-024-01100-3 Cholesterol crystals (CCs) have a pathogenic role in various cardiovasculardiseases, particularly atherosclerosis.
is at an all time high, with 942k cardiovasculardisease-related deaths in 2022, up by 10k from 2021. However, theres light at the end of the cardiovascular tunnel thanks to advancements in drugs like GLP-1s and new cholesterol controls, which mean heart disease isnt a death sentence like it used to be.
BackgroundEmerging genetic and observational evidence indicates that remnant cholesterol (RC) is a significant residual risk factor for cardiovasculardiseases. However, there is a relative paucity of evidence exploring the correlation among RC, lipid ratios, and atherosclerotic lesion severity.
More than 70% of American Indian young adults aged 20-39 and 50% of American Indian teens have cholesterol levels or elevated fat in the blood that put them at risk for cardiovasculardisease, a new study suggests.
adults have high cholesterol, according to the Centers for Disease Control and Prevention (CDC). Untreated, high cholesterol can lead to heart disease and stroke, which are two of the top causes of death in the U.S. Nearly two in five U.S.
Researchers have discovered that certain components of so-called 'good' cholesterol -- high-density lipoproteins (HDL) -- may be associated with an increased prevalence of cardiovasculardisease.
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a Phase II trial.
Niacin , a common B vitamin once recommended to patients as a way to help lower cholesterol, has been linked to cardiovasculardisease, Cleveland Clinic researchers announced Feb.
Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovasculardisease (ASCVD), explaining how industrially produced trans-unsaturated fatty acids in our food significantly promote ASCVD and encouraging lawmakers to impose regulations on the (..)
This randomized clinical trial evaluates the safety and efficacy of lerodalcibep vs placebo in reduction of low-density lipoprotein cholesterol in patients with or at risk of cardiovasculardisease.
This systematic review and individual patient data meta-analysis investigates the association of an alternative low-density lipoprotein (LDL) strategy with differences in long-term efficacy and safety in patients with atherosclerotic cardiovasculardisease (ASCVD) compared with a high-intensity statin strategy.
Houston Methodist researchers have discovered that certain components of so-called "good" cholesterolhigh-density lipoproteins (HDL)may be associated with an increased prevalence of cardiovasculardisease.
The app also recorded other significant heart health risk factors, such as cholesterol, weight, and physical activity via integration with external sources including electronic medical records and fitness trackers. Change in blood pressure (BP), LDL cholesterol, and weight were evaluated from baseline to follow up.
This year, the cholesterol charity took on an international theme, looking at the global cardiovasculardisease (CVD) prevention picture. There was also a particular focus on women and CVD disease, alongside a review of how familial hypercholesterolaemia (FH) care has advanced in recent decades.
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. The post Global Trends in CardiovascularDiseases: Insights from the 2023 Almanac appeared first on Cardiology Update. Original article: Mensah GA et al.
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovasculardisease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4
Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovasculardisease risk among women enrolled in the Women’s Health Study.
The analyses of longitudinal changes in remnant cholesterol (RC) and cardiovasculardisease (CVD) remains are limited. The objective of the study was to investigate the associations of longitudinal changes in.
Cardiovasculardisease (CVD) represents a significant global health challenge, characterized by high incidence rates and substantial morbidity and mortality. A newer index, the Cholesterol, High-Density Lipopr.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Reduction in low-density lipoprotein cholesterol (LDL-C) levels has consistently demonstrated a reduced risk of atherosclerotic cardiovasculardisease (ASCVD). There is extensive evidence from randomized trials that demonstrates the effectiveness of lipid-lowering agents in reducing ASCVD-related events.
When they become fathers, men who have an unhealthy, high-cholesterol diet can cause increased risk of cardiovasculardisease, or CVD, in their daughters, a mouse study has found.
A recent trial of a novel gene-editing technique that lowered dangerously high cholesterol by up to 55% has generated talk of a new front opening against cardiovasculardisease, which kills nearly 700,000 Americans each year and is the nation's leading cause of death.
Taking a long-term view of cardiovasculardisease prevention is an attractive strategy since atherosclerosis begins early in life and progresses over decades. Lowering low-density lipoprotein (LDL) cholesterol levels and improving lifestyle habits are mainstay strategies for reducing the risk of cardiovasculardisease.1
The objective of this study was to examine the prospective association between plasma RvD2 and the risk of atherosclerotic cardiovasculardisease (ASCVD) at the population level.Methods and ResultsA cohort of 2633 community‐dwelling individuals aged 35–60 years was followed for 8 years in this study. P<0.001).
Researchers have discovered the mechanism by which cholesterol in our diet is absorbed into our cells. This discovery opens up new opportunities for therapeutic intervention to control cholesterol uptake that could complement other therapies and potentially save lives.
Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovasculardisease. Journal of the American Heart Association, Ahead of Print. Barriers include poor adherence, clinical inertia, concern for side effects, cost, and complex prior authorization processes.
Older general population-based studies found an inverse association between serum HDL-cholesterol and both cardiovasculardisease (CVD) events and mortality, but more recent data have suggested a U-shaped rela.
But a new study suggests the drug may also provide a surprising and life-saving benefit: lowering cholesterol and cutting the overall risk of cardiovasculardisease. The drug finasteride, also known as Propecia or Proscar, treats male pattern baldness and enlarged prostate in millions of men worldwide.
BackgroundOne measurement of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is considered to be associated with insulin resistance and cardiovasculardisease (CVD) risk. This association remained significant even after further adjustment for single measurements of NHHR.
In my opinion, or should I say ‘allegedly’ what actually happened here was that Barney Calman had heard from various cardiology experts that cholesterol and statin ‘deniers’ were causing people to stop taking their drugs. As a writer and lecturer, he has a specialist interest in the epidemiology of cardiovasculardisease.
Atherosclerosisa key driver of cardiovasculardisease (CVD)continues to be a significant global health issue. These cases are particularly challenging because traditional prevention strategies, which target known risks like high LDL cholesterol, hypertension, diabetes, and smoking, may not apply.
BACKGROUND:Cholesterol efflux capacity (CEC) predicts cardiovasculardisease independently of high-density lipoprotein (HDL) cholesterol levels. Enhanced CEC, as seen with the smaller particles, predicts decreased cardiovasculardisease risk. Circulation, Ahead of Print.
Patients with chronic inflammatory disorders such as psoriasis have an increased risk of cardiovasculardisease and elevated levels of LL37, a cathelicidin host defense peptide that has both antimicrobial and proinflammatory properties.
This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovasculardisease.
(MedPage Today) -- LONDON -- A combination of three factors -- high-sensitivity C-reactive protein (hsCRP), LDL cholesterol, and lipoprotein(a), or lp(a) -- independently predicted cardiovasculardisease over 30 years in women who were initially.
A recently unveiled cardiovasculardisease risk calculator that measures a patient's risk for heart attack and stroke is better calibrated and more precise than its previous version, but if current treatment guidelines for cholesterol and blood pressure therapy remain unchanged, the new calculator may have unintended consequences, according to research (..)
Researchers have identified a new pathway that contributes to cardiovasculardisease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease.
Remnant cholesterol (remnant-C) contributes to atherosclerotic cardiovasculardisease (ASCVD), particularly in individuals with impaired glucose metabolism. Patients with impaired glu.
Despite this, including them to a person’s food regimen can assist raise “suitable” ldl cholesterol degrees. However, they'll now no longer assist decrease “awful” ldl cholesterol with out extra food regimen changes. Some declare it could additionally decrease low-density lipoprotein (LDL) ldl cholesterol, called awful ldl cholesterol.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content